MedTrace Logo

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

NCT00808249 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 725

Last updated 2011-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

Conditions

  • Anxiety Disorders

Interventions

DRUG

AZD7325

2 tablets taken twice a day for 28 days

DRUG

AZD7325

2 tablets taken twice a day for 28 days

DRUG

AZD7325

2 tablets taken twice a day for 28 days

DRUG

Placebo

2 tablets taken twice a day for 28 days

Sponsors & Collaborators

Principal Investigators

  • Mark A. Smith, MD, PhD · AstraZeneca

  • David V. Sheehan · University of South Florida College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808249 on ClinicalTrials.gov